Search results for "state"

showing 10 items of 9165 documents

Efficacy of a coordinated strategy for containment of multidrug-resistant Gram-negative bacteria carriage in a Neonatal Intensive Care Unit in the co…

2021

AbstractBackgroundAntimicrobial resistance in neonatal intensive care unit (NICU) patients is a threat, due to the frequent use of antimicrobial treatment and invasive devices in fragile babies. Since 2014 an active surveillance program of multidrug-resistant Gram-negative bacteria (MDR-GNB) carriage has been in place in the five NICUs of Palermo, Italy. In 2017 an increase in the prevalence of MDR-GNB, and in particular of extended-spectrum β-lactamases-producingKlebsiella pneumoniae(ESBL-KP), was observed in “Civico” hospital NICU.AimTo assess the impact of a coordinated intervention strategy in achieving long-lasting reduction of MDR-GNB prevalence in the NICU.MethodsRectal swabs were ob…

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyNeonatal intensive care unit030106 microbiologyExtended spectrum β lactamases producing klebsiella pneumoniaeContext (language use)Drug resistanceMicrobial Sensitivity TestsAntimicrobial resistancelcsh:Infectious and parasitic diseases03 medical and health sciences0302 clinical medicineAntibiotic resistanceMedical microbiologyNeonatal intensive care unitInternal medicineDrug Resistance Multiple BacterialIntensive Care Units NeonatalGram-Negative BacteriamedicineHumansPharmacology (medical)lcsh:RC109-216030212 general & internal medicineNeonatal intensive care unit.Cross InfectionInfection ControlActive surveillance programbusiness.industryResearchPublic Health Environmental and Occupational HealthInfant NewbornAntimicrobialMulti-drug resistant gram-negative bacteriaElectrophoresis Gel Pulsed-FieldInfectious DiseasesCarriageItalyIntervention strategyCarrier StateFemaleSample collectionbusinessGram-Negative Bacterial Infections
researchProduct

Re-definition and supporting evidence toward Fanconi Anemia as a mitochondrial disease: Prospects for new design in clinical management

2021

Fanconi anemia (FA) has been investigated since early studies based on two definitions, namely defective DNA repair and proinflammatory condition. The former definition has built up the grounds for FA diagnosis as excess sensitivity of patients' cells to xenobiotics as diepoxybutane and mitomycin C, resulting in typical chromosomal abnormalities. Another line of studies has related FA phenotype to a prooxidant state, as detected by both in vitro and ex vivo studies. The discovery that the FA group G (FANCG) protein is found in mitochondria (Mukhopadhyay et al., 2006) has been followed by an extensive line of studies providing evidence for multiple links between other FA gene products and mi…

0301 basic medicineMitochondrial DNAMitochondrial DiseasesMitomycinMitochondrial diseaseClinical BiochemistryDiepoxybutaneReview ArticleMitochondrionBiologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFanconi anemiaFANCGmedicineHumansClastogenCarnitinelcsh:QH301-705.5Coenzyme Q10lcsh:R5-920ProteinOrganic ChemistryMitochondrial nutrientProteinsmedicine.diseaseMitochondrial diseaseFanconi AnemiaPhenotypeClastogens030104 developmental biologylcsh:Biology (General)chemistryProoxidant stateCancer researchMitochondrial nutrientsMitochondrial dysfunctionlcsh:Medicine (General)030217 neurology & neurosurgeryHumanmedicine.drugRedox Biology
researchProduct

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences

2018

Myotonic dystrophy type 1 and type 2 (DM1, DM2) are caused by expansions of CTG and CCTG repeats, respectively. RNAs containing expanded CUG or CCUG repeats interfere with the metabolism of other RNAs through titration of the Muscleblind-like (MBNL) RNA binding proteins. DM2 follows a more favorable clinical course than DM1, suggesting that specific modifiers may modulate DM severity. Here, we report that the rbFOX1 RNA binding protein binds to expanded CCUG RNA repeats, but not to expanded CUG RNA repeats. Interestingly, rbFOX1 competes with MBNL1 for binding to CCUG expanded repeats and overexpression of rbFOX1 partly releases MBNL1 from sequestration within CCUG RNA foci in DM2 muscle ce…

0301 basic medicineModels MolecularProtein Conformation alpha-Helical[SDV]Life Sciences [q-bio]General Physics and AstronomyGene ExpressionRNA-binding proteinCrystallography X-Raychemistry.chemical_compoundMOLECULAR-BASISGene expressionMBNL1Myotonic DystrophyComputingMilieux_MISCELLANEOUSMultidisciplinaryCHLORIDE CHANNELQRNA-Binding ProteinsRecombinant Proteins3. Good healthCell biologyCONGENITAL HEART-DISEASEDrosophila melanogasterThermodynamicsSKELETAL-MUSCLERNA Splicing FactorsCUG REPEATSProtein BindingRNA Splicing Factorsmusculoskeletal diseasesSTEADY-STATEcongenital hereditary and neonatal diseases and abnormalitiesScienceRBFOX1BiologyMyotonic dystrophyBinding CompetitiveGeneral Biochemistry Genetics and Molecular BiologyArticle03 medical and health sciencesmedicineEscherichia coliAnimalsHumansProtein Interaction Domains and MotifsBinding siteNucleotide MotifsMuscle SkeletalSPLICING REGULATOR RBFOX2MUSCLEBLIND PROTEINSBinding SitesPRE-MESSENGER-RNARNAGeneral Chemistrymedicine.diseaseDisease Models AnimalKinetics030104 developmental biologychemistryTRIPLET REPEATRNAProtein Conformation beta-Strand3111 Biomedicine
researchProduct

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma

2016

Background: NF-κB signalling appears deregulated in breast tumours. The purpose of this study was to determine whether the non-canonical NF-κB pathway, is activated in oestrogen receptor positive (ER+) breast cancer, to identify any correlation between its activity and the clinico-pathological phenotype and to explore whether NF-κB2 and RelB subunits and/or any of their target genes might be used as a predictive marker. Methods: Two independent cohorts of ER+ early breast cancer patients treated with adjuvant endocrine therapy were included in the study. Activation of RelB and NF-κB2 subunits was determined in a training set of 121 patients by measuring DNA-binding activities in nuclear ext…

0301 basic medicineOncologyAdultCancer Researchmedicine.medical_specialtyBreast NeoplasmsER-positiveNF-κBCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerbreast cancernon-canonicalInternal medicinemedicineHumansMolecular DiagnosticsAgedAged 80 and overPredictive markerOncogenebusiness.industryRELBNF-kappa BMiddle Agedmedicine.diseasePrognosis030104 developmental biologyOncologyReceptors Estrogen030220 oncology & carcinogenesisFemaleLiver cancerBreast carcinomabusinessEstrogen receptor alphaBritish Journal of Cancer
researchProduct

Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen T…

2020

Frailty syndrome is a functional state that includes a loss of ability to react to stressors, and is associated with poor outcomes, morbidity and premature mortality. The first line treatment in many men with prostate cancer (PCa) consists of an androgen-deprivation therapy (ADT) which can promote or favor frailty syndrome and ADT may therefore favor the progression of frailty over time. Among the pathophysiological bases of frailty, the presence of chronic low-grade inflammation has been associated with its adverse outcomes, but longitudinal studies are needed to validate these biomarkers. In this study, we prospectively evaluate frailty syndrome and blood inflammatory markers (IL1-beta, I…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyleukocytesgeriatric assessmentLymphocyteFrailty syndromeInflammationinterleukin-1 betalcsh:RC254-282Article03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineInterleukin 6Receiver operating characteristicbiologybusiness.industryinterleukin-6C-reactive proteinlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologymedicine.anatomical_structureOncologyinflammation030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)biomarkermedicine.symptombusinessCancers
researchProduct

The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.

2017

<b><i>Background/Aim:</i></b> Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. <b><i>Subjects and Methods:</i></b> In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. <b><i>Results:</i></b> Radium-223 was well tolerated, with a m…

0301 basic medicineOncologyDrugRadium-223MaleCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAntineoplastic AgentsBone NeoplasmsDocetaxel03 medical and health sciencesProstate cancer0302 clinical medicineQuality of lifeInternal medicinemedicineHumansmedia_commonAgedRetrospective StudiesAged 80 and overRadioisotopesbusiness.industryBone metastasisRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseProstatic Neoplasms Castration-Resistant030104 developmental biologyOncologyDocetaxelItaly030220 oncology & carcinogenesisQuality of LifeAlkaline phosphatasePrednisoneTaxoidsRadium-223 Bone metastasis Prostate cancer Radiopharmaceuticals Metastatic castration-resistant prostate cancer Quality of Lifebusinessmedicine.drugRadiumOncology
researchProduct

Prognosis and cure of long-term cancer survivors: A population-based estimation.

2019

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.…

0301 basic medicineOncologyMaleCancer ResearchTime FactorsSettore MED/42 - Igiene Generale E Applicata0302 clinical medicineCancer SurvivorsProstateNeoplasmsThyroid cancerOriginal Researcheducation.field_of_studyRelative survivalMortality rateMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosispopulation-based cancer registriemedicine.anatomical_structureOncologyItaly030220 oncology & carcinogenesiscancer cure Italy population-based cancer registries prevalence survivalFemaleCancer PreventionAdultmedicine.medical_specialtypopulation-based cancer registriesAdolescentPopulationprevalenceSocio-culturalelcsh:RC254-282survival03 medical and health sciencesYoung AdultLife ExpectancyInternal medicinemedicinepopulation‐based cancer registriesHumansRadiology Nuclear Medicine and imagingcancer cureeducationAgedEstimationbusiness.industryCancerModels Theoreticalmedicine.disease030104 developmental biologyLife expectancycancer cure; Italy; population-based cancer registries; prevalence; survivalbusinessCancer medicine
researchProduct

Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review

2016

Prostate cancer, the second most frequently diagnosed cancer in males worldwide, is estimated to be diagnosed in 1.1 million men per year. Introduction of PSA testing substantially improved early detection of prostate cancer, however it also led to overdiagnosis and subsequent overtreatment of patients with an indolent disease. Treatment outcome and management of prostate cancer could be improved by the development of non-invasive biomarker assays that aid in increasing the sensitivity and specificity of prostate cancer screening, help to distinguish aggressive from indolent disease and guide therapeutic decisions. Prostate cancer cells release miRNAs into the bloodstream, where they exist …

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyOverdiagnosisDiseaseReviewExosomesManagement of prostate cancer03 medical and health sciencesProstate cancer0302 clinical medicinePredictive Value of TestsInternal medicinemedicineBiomarkers TumorHumansCell-free miRNAsGenetic TestingLiquid biopsyOverdiagnosisProstate cancerLiquid biopsybusiness.industryGene Expression ProfilingCancerDisease ManagementProstatic NeoplasmsBiological TransportExtracellular vesiclesmedicine.diseasePrognosisBody FluidsMicroRNAs030104 developmental biologyProstate cancer screeningOncology030220 oncology & carcinogenesisImmunologyMolecular MedicineBiomarker (medicine)businessTranscriptomeMicrovesiclesBiomarkersMolecular Cancer
researchProduct

Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.

2017

The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA res…

0301 basic medicineOncologyMalemedicine.medical_specialtyCancer ResearchDocetaxelprostatic neoplasm03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineabirateroneAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPharmacology (medical)Neoplasm MetastasisSurvival rateAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryandrogen antagonistRetrospective cohort studyMiddle AgedProstate-Specific Antigenmedicine.diseasedrug therapyProstate-specific antigenProstatic Neoplasms Castration-Resistant030104 developmental biologyDocetaxelTolerabilitymetastatic castration-resistant prostate cancerOncology030220 oncology & carcinogenesisPrednisoneAndrostenesKallikreinsTaxoidsbusinessmedicine.drugAnti-cancer drugs
researchProduct

Quantitative determination of tumor platinum concentration of patients with advanced Breast, lung, prostate, or colorectal cancers undergone platinum…

2017

Context: Previous studies have reported direct relationship between tumor reduction and its platinum concentration following platinum-based (Pt-based) chemotherapy. However, quantitative data of tumor platinum concentration have not yet been reported for the most common cancers. Aims: Determination of tumor platinum concentration of breast, lung, prostate, and colorectal cancers after Pt-based chemotherapy; and evaluation of the influence of chemo drug type, chemotherapy regimen, and time lapse from last chemotherapy on tumor platinum concentration. Materials and Methods: Tumor samples of patients with advanced breast, lung, prostate, and colorectal cancers undergone Pt-based chemotherapy w…

0301 basic medicineOncologyMalemedicine.medical_specialtyLung NeoplasmsColorectal cancermedicine.medical_treatmentcolorectal cancerBreast Neoplasmsplatinum concentrationlcsh:RC254-28203 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerBreast cancerDrug TherapyProstateInternal medicineNeoplasmsmedicineHumansRadiology Nuclear Medicine and imagingLung cancerPlatinumChemotherapybusiness.industryProstatic NeoplasmsGeneral Medicinemedicine.diseaseprostate cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenRegimenlung cancer030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemalebusinessColorectal NeoplasmsJournal of cancer research and therapeutics
researchProduct